Breaks Categories: News

ThursdayMay 14, 2026 9:50 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage neurology and oncology assets. Following quarter end, the company strengthened its balance sheet with a $22.5 million private placement, which, together with existing cash, is expected to support operations beyond 12 months as CNS pursues asset acquisitions and explores out-licensing opportunities for its legacy glioblastoma programs. To view the full press release, visit https://ibn.fm/HP5Xy About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive…

Continue Reading

ThursdayMay 14, 2026 9:40 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research

Kairos Pharma (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches. To view the full press release, visit https://ibn.fm/WuBOf About Kairos Pharma, Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune…

Continue Reading

ThursdayMay 14, 2026 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives. To view the full press release, visit https://ibn.fm/guMCF About HeartBeam, Inc. HeartBeam,…

Continue Reading

WednesdayMay 13, 2026 11:31 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces First Patient Dosed in Phase 1b Trial of Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), alongside Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle(TM) formulation of everolimus for patients with advanced mTOR-sensitive solid tumors. The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity across patient cohorts including HR-positive/HER2-negative breast cancer and multiple additional tumor types, with Sapu003 developed as a weekly IV formulation intended to address limitations associated with oral everolimus delivery, including variable absorption and dose-limiting toxicity. To view the full press release, visit https://ibn.fm/JuGIs About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development…

Continue Reading

WednesdayMay 13, 2026 9:35 am

BioMedNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in BioMedWire editorial coverage examining the rapid growth of the GLP-1 market, with the company highlighted for its subsidiary GlucaPharm Inc. and its development of GEP-44, a patented triple agonist peptide licensed from Syracuse University. The editorial notes that GEP-44 is designed to target GLP-1 and peptide YY receptors Y1 and Y2, positioning SureNano as an emerging microcap participant seeking to address limitations of first-generation GLP-1 therapies, including efficacy, tolerability and delivery flexibility. The coverage also…

Continue Reading

WednesdayMay 13, 2026 9:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around effective central nervous system drug delivery, with the company highlighted for its proprietary intranasal nose-to-brain delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial points to rising global Alzheimer’s cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies, positioning Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success. The coverage also places Oncotelic alongside major biopharma and advanced therapeutics…

Continue Reading

WednesdayMay 13, 2026 9:10 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Spotlighted in BioMedWire Editorial on AI-Driven Impairment Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in BioMedWire editorial coverage highlighting the growing demand for real-time, noninvasive impairment detection technologies, with the company positioned as a differentiated player leveraging artificial intelligence and voice analysis to identify intoxication from brief speech recordings. The editorial underscores the limitations of conventional detection tools such as breathalyzers, blood draws and urine testing, noting MindBio’s focus on scalable, real-time assessment across multiple substances for potential applications in workplace safety, law enforcement, healthcare and public health. The coverage also…

Continue Reading

WednesdayMay 13, 2026 9:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Enters $4.4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for the purchase and sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share in a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The company also announced a concurrent private placement of unregistered warrants and said it plans to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel. To view the full press release, visit https://ibn.fm/6Dy4I ABOUT LANTERN PHARMA INC. Lantern Pharma Inc. (Nasdaq: LTRN) is a…

Continue Reading

TuesdayMay 12, 2026 11:52 am

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising.  SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its placement in a BioMedWire editorial examining the evolution of GLP-1 therapies and emerging innovation in obesity and metabolic disease treatment. The editorial highlights SureNano’s subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the rapidly expanding GLP-1 market, as demand continues to grow for next-generation therapies targeting obesity, type 2 diabetes and related chronic conditions. To view the full press release, visit https://ibn.fm/sv4Fw About SureNano Science Ltd. SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical…

Continue Reading

TuesdayMay 12, 2026 11:08 am

BioMedNewsBreaks — Qdrant Powers Sapu AI Platform Indexing 28 Million PubMed Abstracts to Accelerate Cancer Research 

Qdrant’s vector database infrastructure supports the AI-powered research platform used by SAPU Bioscience, a subsidiary of Oncotelic Therapeutics Inc. (OTCQB: OTLC), enabling large-scale biomedical literature analysis SAPU’s platform has indexed 28 million PubMed abstracts into a single searchable collection, supporting AI-assisted research workflows and peer-reviewed scientific output The AI ecosystem aligns with Oncotelic’s broader strategy of integrating artificial intelligence, nanoparticle development and accelerated drug discovery platforms In a blog post by Daniel Azoulai, Qdrant highlighted how Sapu, an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers, uses Qdrant Cloud infrastructure to power an AI research platform capable of indexing and querying all 28 million PubMed abstracts in a single searchable collection, helping accelerate biomedical…

Continue Reading